Search Results

Skyhawk Therapeutics, Inc. announced the promotion of Clint Musil, former Chief Financial Officer of Skyhawk Therapeutics, to Chief Executive Officer and the appointment of Bill Haney, former Chief Executive Officer and Co-founder of Skyhawk Therapeutics, to Executive Chairman of the Board of Directors.

June 11, 2024

·

5 min read

Press Releases

Skyhawk Therapeutics Presents at Huntington’s Disease Youth Organization HDYO International Congress 2025

March 17, 2025

·

2 min read

Genetown

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases.

April 22, 2024

·

7 min read

Business

Ipsen, Skyhawk Ink Potential $1.8B Deal to Target RNA in Neuro Diseases

Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.

April 22, 2024

·

2 min read

·

Tristan Manalac

Genetown

Skyhawk Therapeutics Receives HREC Approval for a Phase 1 Study of its SKY-0515 RNA-Targeting Small Molecule for Huntington’s Disease

Skyhawk Therapeutics today announced the Australian Human Research Ethic Committee (HREC) approval by Australian regulators for a clinical trial for Skyhawk’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD).

October 23, 2023

·

3 min read